Betagenon AB announces investment and collaboration with Hong Kong-based MCG Technology Group Ltd
Betagenon AB, a Sweden-based biotech company focused on development of AMPK activator compounds, and MCG Technology Group Ltd, a Hong Kong-based biotech investment group, today announced that MCG Technology Group will invest in and collaborate with Betagenon.MCG Technology Group will invest 2M USD in exchange for Betagenon equity. Additionally, both parties will collaborate to test Betagenon’s AMPK activator compound in patients with heart failure with preserved ejection fraction (HFpEF). In return for further equity in Betagenon, the study will be delivered via MCG Technology Group’s